TherapeuticsMD Inc Market Cap ($20.60 Million)
Market Cap & Net Worth: TherapeuticsMD Inc (TXMD)
TherapeuticsMD Inc market cap. TherapeuticsMD Inc (NASDAQ:TXMD) has a market capitalization of $20.60 Million ($20.60 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24856 globally and #5305 in its home market, demonstrating a -1.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TherapeuticsMD Inc's stock price $1.78 by its total outstanding shares 11574362 (11.57 Million). Also see TXMD operating cash flow for how efficiently the company converts equity into cash flow.
TherapeuticsMD Inc Market Cap History (2015–2026)
TherapeuticsMD Inc market cap history from 2015 to 2026. Data shows change from $6.00 Billion to $20.60 Million (-37.28% CAGR). Check today's stock price for TherapeuticsMD Inc for real-time trading data and today's change.
Index Memberships
TherapeuticsMD Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #698 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2293 of 3165 |
Weight: TherapeuticsMD Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
TherapeuticsMD Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TherapeuticsMD Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of TherapeuticsMD Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
6.24x
TherapeuticsMD Inc's market cap is 6.24 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.34 Billion | $19.36 Million | -$89.88 Million | 172.51x | N/A |
| 2017 | $3.50 Billion | $16.78 Million | -$76.93 Million | 208.34x | N/A |
| 2018 | $2.20 Billion | $16.10 Million | -$132.62 Million | 136.96x | N/A |
| 2019 | $1.40 Billion | $49.65 Million | -$176.15 Million | 28.21x | N/A |
| 2020 | $700.25 Million | $64.87 Million | -$183.52 Million | 10.79x | N/A |
| 2021 | $205.73 Million | $2.57 Million | -$172.41 Million | 79.96x | N/A |
| 2022 | $64.70 Million | $69.96 Million | $112.00 Million | 0.92x | 0.58x |
| 2023 | $26.04 Million | $1.30 Million | -$10.28 Million | 20.00x | N/A |
| 2024 | $9.95 Million | $1.76 Million | -$2.18 Million | 5.65x | N/A |
| 2025 | $18.87 Million | $3.02 Million | -$569.00K | 6.24x | N/A |
Competitor Companies of TXMD by Market Capitalization
Companies near TherapeuticsMD Inc in the global market cap rankings as of November 4, 2026. Also see balance sheet size of TherapeuticsMD Inc for a full breakdown of the balance sheet.
Key companies related to TherapeuticsMD Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #534 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #580 globally with a market cap of $46.03 Billion USD ( CN¥314.55 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #534 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.90 |
| #580 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.03 Billion | CN¥49.31 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of TherapeuticsMD Inc (2015–2026)
Market capitalization of TherapeuticsMD Inc from 2015 to today. Between 2015 and today, TherapeuticsMD Inc's market cap moved from $6.00 Billion to $ 20.60 Million, with a yearly change of -37.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $20.60 Million | +9.20% |
| 2025 | $18.87 Million | +89.53% |
| 2024 | $9.95 Million | -61.78% |
| 2023 | $26.04 Million | -59.75% |
| 2022 | $64.70 Million | -68.55% |
| 2021 | $205.73 Million | -70.62% |
| 2020 | $700.25 Million | -50.00% |
| 2019 | $1.40 Billion | -36.48% |
| 2018 | $2.20 Billion | -36.92% |
| 2017 | $3.50 Billion | +4.68% |
| 2016 | $3.34 Billion | -44.36% |
| 2015 | $6.00 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of TherapeuticsMD Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.60 Million USD |
| MoneyControl | $20.60 Million USD |
| MarketWatch | $20.60 Million USD |
| marketcap.company | $20.60 Million USD |
| Reuters | $20.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About TherapeuticsMD Inc
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vag… Read more